AOD-9604 for Weight Loss: What the Research Shows

Growth hormone has known fat-burning effects but full GH therapy comes with significant side effects. Researchers isolated the fat-burning portion (C-terminal fragment) and modified it to create AOD-9604 — delivering fat metabolism benefits without full GH side effects, without affecting blood sugar or IGF-1 levels.

• Lipolysis Stimulation: Activates fat breakdown similarly to GH
• Lipogenesis Inhibition: Blocks new fat cell formation
• No IGF-1 Elevation: Unlike full GH
• No Blood Sugar Impact: Avoids GH's diabetogenic effects

Mixed research history:

• Animal Studies: Obese mice showed significant fat reduction without IGF-1 changes.
• Phase II: Modest but significant fat loss over 12 weeks.
• Phase III: Failed to meet primary endpoints — leading to its shelving as a drug.
• GRAS Status: FDA granted GRAS status in 2020, indicating favorable safety.

Evidence level: Mixed. Safety is well-established but efficacy for significant weight loss is debated.

• Dosage: 300 mcg per day subcutaneously
• Timing: Fasted (morning or before bed)
• Injection: Abdominal subcutaneous
• Cycle: 8–12 weeks

• Week 1–4: Subtle changes; improved fat mobilization during exercise
• Week 4–8: Measurable fat loss with proper diet and exercise
• Week 8–12: More noticeable body composition changes

Expectations should be realistic — AOD-9604 is not as dramatic as semaglutide.

Ascension Peptides offers research-grade AOD-9604:

• ≥98% purity via third-party HPLC
• Published COAs
• Proper lyophilized format